Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison

(1) Background: The relative efficacy and safety of brigatinib compared with other next-generation anaplastic lymphoma kinase (ALK) inhibitors remains unclear, as first-line head-to-head trials have not been conducted. (2) Methods: Electronic databases were systematically searched for eligible rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yongfeng, Zhu, Fanfan, Zhang, Wenxin, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181407/
https://www.ncbi.nlm.nih.gov/pubmed/35683354
http://dx.doi.org/10.3390/jcm11112963

Ejemplares similares

Ejemplares similares